Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182516 | 0.89 | GRM5 (0.57) | GRM5MAPK10GABRG2GABRB3GABRA5 | |
| SCHEMBL182168 | 0.79 | GRM5 (0.67) | GRM5MAPK10GABRG2GABRB3GABRA5 | |
| SCHEMBL2708508 | 0.79 | STIM1 (0.43) | CA1CA2 | |
| SCHEMBL17125346 | 0.79 | GRM5 (0.54) | GRM5MAPK10GABRG2GABRB3GABRA5 | |
| SCHEMBL181880 | 0.78 | GRM5 (0.56) | GRM5MAPK10CTSSCTSKCLK4 | |
| SCHEMBL182394 | 0.78 | GRM5 (0.56) | GRM5MAPK10CTSSIDO1 | |
| SCHEMBL182440 | 0.78 | GRM5 (0.56) | GRM5MAPK10ADORA2ACTSSCTSK | |
| SCHEMBL17125345 | 0.76 | GRM5 (0.51) | GRM5MAPK10ADORA2ACTSSCTSK | |
| SCHEMBL182345 | 0.75 | GRM5 (0.53) | GRM5MAPK10CA1CA2 | |
| SCHEMBL182146 | 0.75 | GRM5 (0.53) | GRM5MAPK10GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | GRM5 1818/4885MAPK10 3636/4885GABRG2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.